

## HeraMED Investor Update Conference Call

**HeraMED Limited (ASX: HMD)** (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, will host a conference call on Friday 18 December 2020 at 10:30 AEDT (Sydney/Melbourne), 7:30 AWST (Perth) to update shareholders on the recent announcements.

The call will be hosted by **David Groberman**, CEO and Co-founder and **Alex Radke**, US General Manager of Operations.

During the call, David and Alex will discuss the results of the recent progress made on its commercialisation strategy.

### Conference call details:

<b>Date:</b>	Friday 18 December 2020
<b>Time:</b>	10:30am (Sydney/Melbourne) / 7:30am (Perth)
<b>To register:</b>	<a href="https://s1.c-conf.com/diamondpass/10011537-d8skzl.html">https://s1.c-conf.com/diamondpass/10011537-d8skzl.html</a>
<b>Dial in details:</b>	You will receive your personal dial in details upon registration

The Company welcomes questions at the end of the conference call. To ask a question, please press \*1 (star 1) on your telephone keypad.

-ENDS-

This announcement was authorised by the Board of HeraMED Limited.

**HeraMED Limited**  
CEO and Co-Founder  
David Groberman  
M: +972 52 699 1188  
E: [David@hera-med.com](mailto:David@hera-med.com)

**Company Secretary**  
Jonathan Hart  
T: +61 2 8379 2961  
E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Media Enquiries**  
Melissa Hamilton  
Media and Capital Partners  
M: +61 4 1775 0274  
E: [Melissa.hamilton@mcpartners.com.au](mailto:Melissa.hamilton@mcpartners.com.au)

### **About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data, and a digital social networking dashboard.